Analysis of Intrahospital Mortality in Patients With Lung Transplant Due to Diffuse Parenchymal Lung Disease

Prudencio-Ribera, V.C.; Blanco, Marta Corral; Jarrín-Estupiñán, M.E.; Alonso-Moralejo, Rodrigo; Pérez-González, Virginia; Martínez-Serna, I.; González-Serrano, M.; Pablo-Gafas, A. de

doi:10.1016/j.transproceed.2018.10.020

Cited by 2 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall IHM of patients with IPF was 12.7% in patients with a single-lung transplant versus 11.0% in those with a double-lung transplant. These mortality results are similar to those described in the Spanish series by Prudencio-Ribera et al, who detected a figure of 13.4% in the group of patients with diffuse interstitial lung disease, with IPF being the most frequent disease, detected in 79.6% of patients [48]. It is worth noting the increase in IHM in 2020 in both groups of patients (not significant), possibly due to the SARS-CoV-2 pandemic, as has been described in other series [21].…”

Section: Discussionsupporting

confidence: 91%

“…Early IHM in single-LTx has shown contradictory results, with an increase in the series by Arango et al [49] and Force et al [16], who recommend resorting to double-LTx in younger patients. On the other hand, in the series by Prudencio-Ribera et al, although long-term survival was higher in the double-LTx group, no significant differences were found at one month between the two options [48]. In any case, the main causes of IHM are post-transplant complications.…”

Section: Discussionmentioning

confidence: 72%

“…Overall, it has been previously described that the survival of transplanted patients is 89% at 3 months, 80% at one year, and 31% at 10 years. The highest number of reported cases of mortality occur in the first 30 days, due to high rejection or infections, mainly by cytomegalovirus [48,49]. The group of patients with diffuse interstitial lung diseases are those with the worst survival rate and the highest IHM, ranging from 10% to 20% [40].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Trends and Outcomes in Lung Transplantation in Patients with and without Idiopathic Pulmonary Fibrosis in Spain during the Period 2016–2020

et al. 2023

View full text Add to dashboard Cite

(1) Background: This paper aims to assess temporal trends (2016–2020) in incidence, patient’s characteristics, complications, length of hospital stay (LOHS) and in-hospital mortality (IHM) among patients with and without idiopathic pulmonary fibrosis (IPF) undergoing lung transplantation (LTx). We also analyse the effect of the COVID-19 pandemic on LTx in these populations. (2) Methods: A retrospective, population-based observational study was conducted using the Spanish National Hospital Discharge Database. Multivariable adjustment was conducted with logistic regression to analyse the IHM. (3) Results: We identified 1777 admissions for LTx during the study period, of which 573 (32.2%) were performed in patients with IPF. The number of hospital admissions for LTx rose from 2016 to 2020, both in patients with and without IPF, but a marked reduction was observed from year 2019 to year 2020. Over time, the proportion of single LTx decreased and bilateral LTx increased significantly in both groups. The incidence of LTx complications increased significantly over time along with the increase in the incidence of IPF. No significant differences in the incidence of complications or in the IHM between patients with and without IPF were found. Suffering any complication of the LTx and pulmonary hypertension were conditions positively associated with IHM in patients with and without IPF. The IHM remained stable from 2016 to 2020 in both study populations and was not affected by the COVID pandemic. (4) Conclusions: Patients with IPF account for almost a third of all lung transplants. The number of LTx increased over time in patients with and without IPF, but a marked reduction was observed from 2019 to 2020. Although the proportion of LTx complications increased significantly over time in both groups, the IHM did not change. IPF was not associated with increased complications or IHM after LTx.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Trends and Outcomes in Lung Transplantation in Patients with and without Idiopathic Pulmonary Fibrosis in Spain during the Period 2016–2020

et al. 2023

View full text Add to dashboard Cite

show abstract

Advances in lung transplantation for interstitial lung diseases

Sadeleer¹,

Verleden²,

Vos³

et al. 2020

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of review Lung transplantation (LTx) is increasingly used as ultimate treatment modality in end-stage interstitial lung diseases (ILDs). This review aims to give an overview of the latest evolutions in this field. Recent findings In the last two years, important new findings regarding LTx outcomes in specific ILD entities have been reported. More data are available on optimization of pre-LTx management of ILD patients especially with regard to pretransplant antifibrotic treatment. Summary LTx is the only treatment option with curative intent for ILDs and is increasingly used for this indication. Several studies have now reported adequate outcomes in different ILD entities, although outcome is shown to be affected by underlying telomeropathies. As new studies could not replicate inferior survival with single compared with double LTx, both options remain acceptable. ILD specialists can beneficially impact on post-LTx outcome by optimizing pre-LTx management: corticosteroids should be avoided, antifibrotics should be initiated whenever possible and BMI and nutritional status optimized, rehabilitation and depression-screening strategies should be implemented in all LTx candidates, as these interventions may all improve postlung transplant survival.

show abstract

Analysis of Intrahospital Mortality in Patients With Lung Transplant Due to Diffuse Parenchymal Lung Disease

Cited by 2 publications

References 7 publications

Trends and Outcomes in Lung Transplantation in Patients with and without Idiopathic Pulmonary Fibrosis in Spain during the Period 2016–2020

Trends and Outcomes in Lung Transplantation in Patients with and without Idiopathic Pulmonary Fibrosis in Spain during the Period 2016–2020

Advances in lung transplantation for interstitial lung diseases

Contact Info

Product

Resources

About